Ecrins Therapeutics
WHO ARE WE ?
Ecrins Therapeutics is a privately held biotech company specialized in the discovery and development of innovative oncology drugs. Our main drug candidate ET-D5 is being developped for human and veterinary oncology applications and is currently in the regulatory preclinical phase. Our other R&D programs are in the discovery phase.
STRATEGY
Ecrins Therapeutics' business strategy involves building a strong intellectual property portfolio with proprietary or licensed-in anti-cancer compounds.
DISCOVERIES
Our discovery of novel molecules with anti-tumor properties was made possible through an innovative approach in phenotypic screening and subsequent confirmation of anti-cancer activity in cancer xenograft models.
Ecrins Therapeutics uses propriety technologies to build a large and diversified product portfolio that it intends to develop and commercialize through licensing agreements with pharmaceutical companies, through joint development and through internal product development programs.
ET-D5
ET-D5 is a small molecule drug candidate that we discovered and are developing for several oncology indications. ET-D5 is a new chemical entity (NCE) that can be taken orally as a tablet.
Our lead candidate ET-D5 is an anti-mitotic and anti-vascular compound. The latter exist in two different classes: (i) anti-angiogenic; (ii) vascular-disrupting agents (VDA). The difference between them is that while the anti-angiogenic drugs prevent neo-vessels formation in the growing tumor, the VDA, for example ET-D5, physically disrupt already established tumor vessels. The destruction of blood vessels by ET-D5 effectively shuts down the supply of O2 and nutrients to cancer cells and provokes a massive intratumoral necrosis. Another mechanism by which ET-D5 targets cancer cells, is by arresting them in division (mitotic arrest), followed by cell death. Most importantly, ET-D5 presents interesting pharmacological properties, good toxicology profile and is active when administered per os.
In addition to our most advanced drug candidate currently in development ET-D5, we have used our proprietary drugs discovery platform to identify six other compounds active against cancer cells. These compounds with diverse chemotypes are currently investigated to better characterize their physicochemical and biological properties. We are searching for funds to launch full scale early-stage drug development programs using these drug candidates.
